Between the devil and the deep blue sea - Balancing the risks and potential benefits of warfarin for older people with atrial fibrillation

Age and Ageing

Volumn 33, Issue 6, 2004, Pages 544-547

  Morgan, Sophie Victoria ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Older people; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AGED; AGING; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DECISION MAKING; PATIENT MONITORING; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX RATIO; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DECISION MAKING; HEMORRHAGE; HUMANS; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 8644284993     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/afh211     Document Type: Review

References (37)

1. Wolf PA et al. Atrial fibrillation as an independent risk factor for stroke; the Framingham study. Stroke 1991; 22: 983-8.
2. Wolf PA, Abott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med 1987; 147: 1561-4.
3. Fisher CM. Reducing the risks of cerebral embolism. Geriatrics 1979; 34: 59-66.
4. Sudlow M, Thomson RG, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: 1167-71.
5. Peterson P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolism complication in atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1: 175-8.
6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
7. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J. Am Coll Cardiol 1991; 18: 349-55.
8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in Atrial Fibrillation study: final results. Circulation 1991; 84: 349-55.
9. Ezekowiz MD, Bridges SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
10. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for the prevention of thromboembolism in atrial fibrillation II study. Lancet 1994; 343: 687-97.
11. EAFT Study Group. European Atrial Fibrillation; secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischaemic attack or minor ischaemic stroke. Lancet 1993; 342: 1255-62.
12. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-57.
13. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469-73.
14. van Walraven et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. JAMA 2002; 288: 2441-8.
15. Laupacis A, Albers G, Dalen J et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S-589S.
16. Predictors of thromboembolism in atrial fibrillation: clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 1-5.
17. Predictors of thromboembolism in atrial fibrillation; echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 6-12.
18. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: 1316-20.
19. Fatkin D, Feneley M. Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography; the relative role of left atrial appendage function, mitral valve disease and spontaneous echocardiographic contrast. Prog Cardiovasc Dis 1996; 39: 57-68.
20. Jones EF, Calafiore P, McNeil J et al. Atrial fibrillation with left atrial spontaneous contrast detected by transoesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996; 78: 425-9.
21. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999; 131: 688-95.
22. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 2000; 109: 45-51.
23. SPAF investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-91.
24. Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJA, Lemmen TH et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999; 319: 958-64.
25. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321-6.
26. Hart RG, Benavente O, Mc Bride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
27. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102: 426s-433s.
28. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-16.
29. The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group. A Randomised trial of anticoagulants versus aspirin after cerebral ischaemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
30. Landefield CS, Goldman I. Major bleeding in outpatients treated with warfarin; incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
31. Franke CL, de Jonge J, van Swieten JC, Op de Coul AAW, van Gijn J. Intracerebral haematoma during anticoagulant treatment. Stroke 1990; 21: 726-30.
32. SPAF III. Adjusted dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
33. Landefeld CS, Beyth RJ. Anticoagulant related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28.
34. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
35. Hylek E et al. Effect of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.
36. Fitzmaurice DA, Hobb FDR, Murray ET, Holder RC, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near patient testing: a randomised controlled trial. Arch Intern Med 2000; 160: 2343-8.
37. SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691.